The yin and yang of CD1d recognition.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Invariant natural killer T cells and their ligands: focus on multiple sclerosis.Immunology · 2015
   Review
2. Organ-specific protective role of NKT cells in virus-induced inflammatory demyelination and myocarditis depends on mouse strain.Journal of neuroimmunology · 2015
   Article
3. Synthesis of a 2"-deoxy-β-GalCer.Molecules (Basel, Switzerland) · 2014
   Article
4. Fine tuning a well-oiled machine: Influence of NK1.1 and NKG2D on NKT cell development and function.International immunopharmacology · 2013
   Review
5. The molecular basis for recognition of CD1d/α-galactosylceramide by a human non-Vα24 T cell receptor.PLoS biology · 2012
   Article

Corrections and comments

• Comment on
  Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens.2012
• Comment on
  Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as